Subscribe (free)
About NaturalNews
Contact Us
Write for NaturalNews
Media Info
Advertising Info
Health news

Study Questions Choice of Hormone Therapy for Prostate Cancer (press release)

Thursday, August 24, 2006 by: NaturalNews
Tags: health news, Natural News, nutrition

Most Viewed Articles
Popular on Facebook
Androgen deprivation therapy, an effective but costly and potentially toxic treatment, is often used to treat advanced prostate cancer.

But a new study suggests that a patient's choice of physician, rather than the stage of his cancer, may determine whether or not he gets the treatment.

Researchers at the University of Texas Medical Branch at Galveston studied the treatment histories of nearly 62,000 men from a Medicare database, age 65 and older, who were diagnosed with prostate cancer. They also looked at data on the patients' 1,802 urologists and the frequency with which they prescribed androgen deprivation therapy.

The therapy, which prevents production of cancer-promoting steroid androgens in cells, is used in approximately half of all prostate cancers, typically for more advanced or metastatic tumors.

According to the study, just 9.7 percent of patients prescribed the therapy received it because of the stage or grade of their tumors. Twenty-one percent seemed to have been prescribed androgen treatment because it was favored by the urologist they saw. In fact, use of the therapy could be attributed to symptoms and other patients' specifics only 4.3 percent of the time, the team said.

The findings "suggest that interventions at the level of the urologist may be an effective way to modify the use of this therapy for prostate cancer," the authors wrote in a prepared statement.

An editorial, written by Dr. Paul F. Schellhammer, of Eastern Virginia Medical School in Norfolk, appears alongside the findings, which appear in the June 21 issue of the Journal of the National Cancer Institute.

Schellhammer said, "the challenge for urologists is to offer men with high-risk, potentially lethal prostate cancer androgen deprivation therapy early in their course of treatment and to avoid the unnecessary risks of androgen deprivation therapy among men with low-risk indolent [slow-moving] disease."

STAY INFORMED! Free subscription to the Health Ranger's email newsletter
Get breaking news alerts on GMOs, fluoride, superfoods, natural cures and more...
Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.